# Human Rotavirus Vaccine Market

> Human Rotavirus Vaccine Market information by type (Rotarix, RotaTeq, Rotavac, Rotavin-M1, Lanzhou lamb, others) by end users (hospitals & clinics, academic and research, others) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.15%
- **2024:** $ 11.3 Billion
- **2025:** $ 12.11 Billion
- **2035:** $ 24.15 Billion
- **Key Players:** Companies such as GlaxoSmithKline (GB), Merck & Co. (US), Sanofi Pasteur (FR), Pfizer (US), Bharat Biotech (IN), Serum Institute of India (IN), Takeda Pharmaceutical Company (JP), Bio Farma (ID) are some of the major participants in the market.

**Report ID:** MRFR/Pharma/2827-HCR · **Pages:** 80 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** May 18, 2026

**URL:** https://www.marketresearchfuture.com/reports/human-rotavirus-vaccine-market-4171

---

## Market Summary

## **Human Rotavirus Vaccine Market Overview**

Human Rotavirus Vaccine Market Size was valued at USD 10.41 Billion in 2023. The Global Human Rotavirus Vaccine industry is projected to grow from USD 11.30 Billion in 2024 to USD 19.97 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.54% during the forecast period (2024 - 2032).

Rotavirus vaccine is used to gain a shield and protect against rotavirus infections which cause severe diarrhea among young children as a part of the population. The market symptoms of rotavirus infection are inclusive of severe diarrhea, vomiting, fever, and abdominal pain which can result in disease. The Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available and gained major momentum in the United States in 2006.** **

**COVID 19 Analysis**

The human rotavirus vaccine market has been one of the affected markets since the coronavirus infection has turned into a pandemic and is facing adversities ever since. The changing way of life and inclinations of individuals is a consequence of the pandemic that sped up a significant change in the useful examples of the market. The primary explanation for this is that the pandemic has introduced significant difficulties for industry and market verticles which are confronting issues to work.

The inaccessibility of unrefined substance for the creation and assembling close by the strategic help nonattendance is pushing for a mass disturbance of the store network instrument. The examples of interest and assembling are distinctive in both the provincial and worldwide areas are vigorously affecting the capacity of the interest to work and the practical limitations that have been forced are likewise adding to the affliction. 

Notwithstanding, to accomplish the past examples and advantage both the makers and interest groups, the public authority is putting resources into innovative work strategies to assist the market with growing a worldwide scale. Likewise, the key market players are en route to curating inventive and imaginative items and dispatching them for an enormous scope. This is being done to assist them with perceiving the items and requests according to the accessibility likewise.** **

## **Human Rotavirus Vaccine Market Dynamics**

**Drivers**

Some major factors are projected to promote the growth of the Human Rotavirus Vaccine Market size in the forecast period that will be ending in 2028. The factors contributing to the growth of the human rotavirus vaccine market include increased development alongside an increase in the number of people with weakened immunity. Also, the market is witnessing an increase in public awareness which has positive attributes in store for the global market during the ongoing forecast period that will be ending in 2028.

Also, there has been a substantial increase in the older chunk population, as well as the general population and live births taking place. These are all aspects that are driving the Human Rotavirus Vaccine Market forward as per the predictions that have been made for the forecast period of 2021-2028. 

**Restraints**

But, the human rotavirus therapeutics market is witnessing a substantial decrease in healthcare expenses in most of the advancing countries. This is one of the major reasons that is restraining the human rotavirus vaccine market from growing during the forecast period that will be ending in 2028. The human rotavirus vaccine market is further, witnessing a rise in the prices of the vaccines and the adverse reactions alongside the increased side effects of the vaccine that are further estimated to bar the human rotavirus vaccine market shortly, as a part of the ongoing forecast period of 2021-2028.** **

**Technology Analysis**

The rise in the production scales of the vaccines is escalating the growth of the human rotavirus vaccine market as per the predictions of the experts for the forecast period of 2021-2028. Rotavirus vaccine is known to be applied to gain prevention against rotavirus infections which can cause severe diarrhea that is more prevalent amongst young children. The symptoms of rotavirus infection are inclusive of severe diarrhea, and other issues like vomiting, fever, and abdominal pain. These issues can cause disease and harm the health of the global target audience.

Rotavirus vaccine is given through the mouth and requires a minimum of two or three doses starting around six weeks of age amongst the youngsters. 

**Study Objectives**

## **Human Rotavirus Vaccine Segments**

The human rotavirus vaccine market revenue is rising because of the excellent performance of the following market segments. They are:

### **Based on the market type**

The human rotavirus vaccine market is segmented based on the market type and includes Rotarix, RotaTeq, rotavac, rotavin-M1, Lanzhou lamb, amongst others. 

### **Based on the market application**

The human rotavirus vaccine market is segmented based on the market applications and includes Hospitals and Clinics, Academic and Research centers. 

### **Based on the market end-users**

The human rotavirus vaccine market is segmented based on the market end-users and includes the demand from pediatricians, gynecologists, and others.** **

**Regional Analysis**

The North American region is likely to dominate the human rotavirus vaccine market. The main reason behind this is the widespread utilization of medications and an increase in the expenses of health care. Further, the human rotavirus vaccine market analysis shows that there is a rapid uptake of new technology and the focus of main research companies. Also, the vaccine research sector in the advanced economies will further boost the growth of the human rotavirus vaccine market trends in the region during the forecast period that will be ending in 2028.** **

**Competitive Landscape**

The human rotavirus vaccine market share is rising because of the performance of the following market players:

**Recent Developments**

**Intended Audience**

**Report Overview**

The human rotavirus vaccine market report is a combination of the diverse market factors that will help the market and lead the way towards the growth scale that has been predicted by the experts for the forecast period of 2024-2032. The human rotavirus vaccine market report helps in understanding the recent developments that have been undertaken by the industry and the ones that will lead to expansion in the ongoing forecast period that will be ending in 2023.

## Market Drivers

### Rising Healthcare Expenditure

Rising healthcare expenditure is a significant factor influencing the Human Rotavirus Vaccine Market. As countries invest more in healthcare infrastructure and services, the allocation of funds towards vaccination programs has increased. This trend is particularly evident in developing nations, where improving child health is a priority.
 
Enhanced healthcare budgets allow for the procurement of vaccines, training of healthcare personnel, and establishment of distribution networks. According to recent data, healthcare spending in many regions has seen a steady increase, which correlates with improved vaccination coverage. The commitment to enhancing public health through vaccination is likely to drive the Human Rotavirus Vaccine Market forward, as more resources become available for the prevention of rotavirus infections.

### Increased Public Awareness and Education

Public awareness and education regarding the benefits of vaccination are pivotal in driving the Human Rotavirus Vaccine Market. Campaigns aimed at informing parents about the dangers of rotavirus and the efficacy of vaccines have proven effective in increasing vaccination rates. Health organizations and non-profits are actively engaged in disseminating information that highlights the importance of immunization in preventing rotavirus-related illnesses.
 
This growing awareness is likely to lead to higher demand for vaccines, as parents become more informed about the health risks associated with rotavirus. Additionally, educational initiatives that emphasize the long-term benefits of vaccination for community health may further enhance the Human Rotavirus Vaccine Market. As public perception shifts towards valuing preventive healthcare, the market could experience significant growth.

### Rising Incidence of Rotavirus Infections

The increasing incidence of rotavirus infections among children appears to be a primary driver for the Human Rotavirus Vaccine Market. According to health organizations, rotavirus is responsible for a significant proportion of severe diarrhea cases in infants and young children, leading to hospitalizations and fatalities. This alarming trend has prompted governments and health authorities to prioritize vaccination programs, thereby enhancing the demand for rotavirus vaccines.
 
The World Health Organization has reported that rotavirus causes approximately 215,000 deaths annually in children under five years of age. Consequently, the heightened awareness of rotavirus's impact on child health is likely to stimulate growth in the Human Rotavirus Vaccine Market, as more countries adopt vaccination strategies to combat this preventable disease.

### Government Vaccination Programs and Policies

Government-led vaccination programs and policies are crucial in shaping the Human Rotavirus Vaccine Market. Many countries have integrated rotavirus vaccines into their national immunization schedules, which has led to increased accessibility and uptake among target populations. For instance, nations that have implemented routine immunization against rotavirus have observed a marked decline in hospitalization rates due to severe diarrhea.
 
The commitment of governments to allocate resources for vaccine procurement and distribution is indicative of the importance placed on child health. Furthermore, international health organizations often provide funding and support for these initiatives, which further bolsters the Human Rotavirus Vaccine Market. As more countries recognize the economic and health benefits of vaccination, the market is poised for continued expansion.

### Technological Innovations in Vaccine Development

Technological innovations in vaccine development are transforming the Human Rotavirus Vaccine Market. Advances in biotechnology and research methodologies have led to the creation of more effective and safer vaccines. For instance, the development of live attenuated vaccines has shown promising results in eliciting strong immune responses with fewer side effects. Furthermore, ongoing research into new formulations and delivery methods may enhance vaccine efficacy and accessibility.
 
The introduction of combination vaccines that protect against multiple pathogens, including rotavirus, could also streamline immunization schedules, making it easier for healthcare providers to administer vaccines. As these innovations continue to emerge, they are likely to attract investment and interest in the Human Rotavirus Vaccine Market, potentially leading to increased market penetration and improved health outcomes.

## Future Outlook

The Human Rotavirus Vaccine Market size is projected to reach USD 24.15 Billion by 2035, growing at a CAGR of 7.15%, driven by increasing vaccination rates and rising awareness of rotavirus infections.

**New opportunities:**

- Expansion into emerging markets with tailored vaccination programs. Development of combination vaccines to enhance immunization coverage. Investment in digital health platforms for vaccine tracking and education.

By 2035, the market is expected to achieve robust growth, solidifying its position in global healthcare.

## Segment Insights

### By Type: Rotarix (Largest) vs. RotaTeq (Fastest-Growing)

In the Human Rotavirus Vaccine Market, the distribution of market share among key vaccines reveals interesting dynamics. Rotarix has emerged as the largest segment holding market share of 58%, primarily due to its extensive clinical usage and favorable efficacy profile. In contrast, RotaTeq is gaining traction as a significant player, attributed to robust endorsements from health organizations and its broad acceptance in varying demographic settings, which enhances its market adoption. The growth trends in this segment exhibit promising potential for the vaccines. RotaTeq is recognized as the fastest-growing vaccine driven by increasing public awareness regarding rotavirus infections and vaccination campaigns. Additionally, innovations in vaccine formulation and the rising demand for preventive healthcare are key drivers for market expansion. The increasing recommendations from pediatric associations further bolster the growth of vaccines like RotaTeq, indicating a trend towards heightened accessibility and utilization.

Vaccine Efficacy: Rotarix (Dominant) vs. RotaTeq (Emerging)

Rotarix is positioned as a dominant force in the Human Rotavirus Vaccine Market due to its comprehensive clinical backing and established efficacy in preventing severe rotavirus gastroenteritis. Its safety profile and long-standing market presence make it an essential choice for healthcare providers. In contrast, RotaTeq, while still establishing its foothold, is regarded as an emerging vaccine with a unique five-valent composition, which enhances its efficacy against multiple rotavirus strains. This innovation is appealing to parents and healthcare practitioners, encouraging adoption in wider demographics. Both vaccines, while differing in market maturity, contribute significantly to the overall goal of reducing rotavirus morbidity and mortality.

### By Application: Hospitals and Clinics (Largest) vs. Academic and Research centers (Fastest-Growing)

In the Human Rotavirus Vaccine Market, Hospitals and Clinics emerge as the dominant application area holding market share of 72%, encompassing the majority of vaccine distribution and administration activities. The strong infrastructure and patient access these healthcare facilities provide enable them to effectively reach large populations, ensuring high vaccination rates against rotavirus. Conversely, Academic and Research centers, although smaller in immediate market share, are crucial in driving innovations and enhancing vaccine formulations, ultimately contributing to the market's progression.

Hospitals and Clinics (Dominant) vs. Academic and Research centers (Emerging)

Hospitals and Clinics play a vital role in the Human Rotavirus Vaccine Market, acting as the primary conduits for vaccine distribution and public health campaigns. Their established patient bases and regulatory support allow these facilities to maintain a robust presence in vaccine administration. On the other hand, Academic and Research centers are emerging as pivotal players in the market, focusing on research and vaccine development. They foster collaboration among scientists, healthcare professionals, and policymakers to enhance vaccine efficacy and uptake. This duality in application not only strengthens the overall market framework but also drives advancements that will aid in combating rotavirus effectively.

### By End-Users: Pediatricians (Largest) vs. Gynecologists (Fastest-Growing)

In the Human Rotavirus Vaccine Market, pediatricians represent the largest segment holding market share of 67%, given their central role in immunizing infants and young children against rotavirus infections. They significantly influence vaccine uptake due to their frequent interactions with the pediatric population. On the other hand, gynecologists are emerging as a vital force in this market, particularly as maternal vaccination programs gain traction. Their role in educating and vaccinating mothers can substantially affect vaccine distribution and acceptance across different demographics. The growth trends within the End-Users segment are notably shaped by increasing awareness of rotavirus-related health issues and the promotion of vaccination campaigns. Pediatricians are capitalizing on their established relationships with parents and caregivers to enhance vaccination rates, thus maintaining their dominant market position. Conversely, gynecologists are rapidly gaining influence as more studies highlight the importance of maternal immunization in protecting infants, positioning them as the fastest-growing segment in this market.

Pediatricians (Dominant) vs. Gynecologists (Emerging)

Pediatricians play a dominant role in the Human Rotavirus Vaccine Market, primarily due to their direct engagement with young patients and their vital influence on immunization schedules. Their extensive knowledge of child health and development empowers them to provide tailored health advice, making them key advocates for rotavirus vaccination. In comparison, gynecologists are emerging in this market as they begin to advocate for maternal immunization, recognizing its importance in safeguarding infants from rotavirus infections. The growing emphasis on preventive health measures during pregnancy has led to increased collaboration between pediatricians and gynecologists, with both specialties working towards improving vaccination coverage. The evolving landscape highlights the importance of integrating [maternal health](https://www.marketresearchfuture.com/reports/maternal-health-market-732) and child vaccination strategies.

## Regional Market Share Analysis

### North America : Leading Market for Vaccines

North America leads in the Human Rotavirus Vaccine Market size, accounting for over 39.82% of the global revenue in 2024. The region's growth is driven by high vaccination rates, robust healthcare infrastructure, and strong regulatory support from agencies like the CDC and FDA. Increasing awareness about rotavirus and its prevention is further propelling demand, alongside government initiatives promoting vaccination programs. Strong immunization coverage, advanced healthcare infrastructure, and regulatory support from public health agencies continue driving rotavirus vaccine adoption.

The United States and Canada are the leading countries in this region, with significant contributions from major pharmaceutical companies such as Merck & Co. and Pfizer. The competitive landscape is characterized by ongoing research and development efforts, with key players focusing on innovative vaccine formulations. The presence of established healthcare systems ensures efficient distribution and accessibility of vaccines, enhancing market growth.

- According to the Centers for Disease Control and Prevention, routine rotavirus vaccination programs have significantly reduced rotavirus-related hospitalization among children in the United States. High pediatric vaccine coverage combined with advanced distribution systems continues reinforcing North America’s leadership in vaccine adoption and preventive healthcare outcomes.

### Europe : Regulatory Support and Innovation

Europe Human Rotavirus Vaccine Market size was valued at USD 3.39 Billion in 2024, making it the second-largest regional market with a 30% share.The region benefits from strong regulatory frameworks and initiatives aimed at increasing vaccination coverage. Countries like Germany and France are leading the charge, with government policies promoting immunization against rotavirus, thus driving demand for vaccines. The European Medicines Agency plays a crucial role in ensuring vaccine safety and efficacy, which further boosts market growth. Government-backed immunization policies, strong healthcare systems, and increasing vaccination awareness continue supporting market growth.

Leading countries in Europe include Germany, France, and the UK, where major players like GlaxoSmithKline and Sanofi Pasteur are actively involved. The competitive landscape is marked by collaborations between public health organizations and pharmaceutical companies to enhance vaccine distribution. The focus on innovative [vaccine technologies](https://www.marketresearchfuture.com/reports/vaccine-technologies-market-11967) and public health campaigns is expected to sustain growth in this region.

- According to European Centre for Disease Prevention and Control, increasing rotavirus vaccination implementation across European countries has contributed to reductions in severe gastroenteritis burden among children. Expanding public immunization programs and strengthened healthcare access support sustained vaccine demand throughout Europe.

### Asia-Pacific : Emerging Market Potential

Asia-Pacific is witnessing rapid growth in the human rotavirus vaccine market, accounting for approximately 25% of the global share. The region's growth is driven by increasing healthcare investments, rising awareness about rotavirus, and government initiatives aimed at improving child health. Countries like India and China are at the forefront, with significant efforts to enhance vaccination coverage and reduce child mortality rates associated with rotavirus infections.

India and China are the leading countries in this region, with key players such as Bharat Biotech and Serum Institute of India making substantial contributions. The competitive landscape is evolving, with local manufacturers focusing on affordable vaccine options to cater to the large population. Collaborations between governments and private sectors are crucial for improving vaccine accessibility and distribution, further propelling market growth.

### Middle East and Africa : Challenges and Opportunities

The Middle East and Africa region is gradually emerging in the human rotavirus vaccine market, holding about 5% of the global share. The growth is primarily driven by increasing healthcare awareness and initiatives aimed at improving child health. However, challenges such as limited healthcare infrastructure and vaccine accessibility persist. Countries like South Africa and Nigeria are making strides in vaccination programs, supported by international health organizations.

South Africa and Nigeria are the leading countries in this region, with efforts focused on enhancing immunization coverage against rotavirus. The competitive landscape includes both local and international players, with organizations like Bio Farma and Takeda Pharmaceutical Company working to improve vaccine availability. Collaborative efforts between governments and NGOs are essential to address the challenges and leverage opportunities for market growth.

## Competitive Benchmarking

The Human Rotavirus Vaccine Market is characterized by a dynamic competitive landscape, driven by increasing awareness of rotavirus infections and the critical need for vaccination in both developed and developing regions. Key players such as GlaxoSmithKline (GB), Merck & Co. (US), and Bharat Biotech (IN) are strategically positioned to leverage their extensive research capabilities and established distribution networks. GlaxoSmithKline (GB) focuses on innovation, particularly in enhancing vaccine efficacy and safety profiles, while Merck & Co. (US) emphasizes strategic partnerships to expand its market reach. Bharat Biotech (IN), on the other hand, is concentrating on regional expansion and affordability, aiming to cater to emerging markets where rotavirus remains a significant health concern. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and accessibility.
In terms of business tactics, companies are localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly evident in the context of the moderately fragmented market structure, where several players vie for market share. The collective influence of these key players shapes the market dynamics, as they engage in strategic collaborations and optimize their operations to meet the growing demand for rotavirus vaccines.
In August 2025, Merck & Co. (US) announced a collaboration with a leading biotechnology firm to enhance its vaccine development pipeline. This strategic move is likely to bolster Merck's position in the market by integrating cutting-edge technologies and accelerating the development of next-generation rotavirus vaccines. Such partnerships may also facilitate access to novel platforms that could improve vaccine delivery and efficacy.
In September 2025, Bharat Biotech (IN) launched a new rotavirus vaccine specifically designed for low-resource settings, which is expected to significantly reduce the cost of vaccination. This initiative not only demonstrates Bharat Biotech's commitment to addressing public health challenges but also positions the company as a leader in providing affordable healthcare solutions in emerging markets. The strategic importance of this launch lies in its potential to increase vaccination rates in regions where access to existing vaccines is limited.
In October 2025, GlaxoSmithKline (GB) unveiled a digital health initiative aimed at improving vaccine awareness and education among healthcare providers and parents. This initiative is indicative of a broader trend towards digitalization in the healthcare sector, where companies are leveraging technology to enhance patient engagement and improve health outcomes. The strategic importance of this move lies in its potential to drive demand for vaccines by fostering a more informed public.
As of October 2025, the competitive trends in the Human Rotavirus Vaccine Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in vaccine development and distribution. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, underscoring the importance of adaptability in a rapidly changing market.

## Recent News & Developments

**Intended Audience**

## Report Scope

| MARKET SIZE 2024 | 11.3(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 12.11(USD Billion) |
| MARKET SIZE 2035 | 24.15(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.15% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | GlaxoSmithKline (GB), Merck & Co. (US), Sanofi Pasteur (FR), Pfizer (US), Bharat Biotech (IN), Serum Institute of India (IN), Takeda Pharmaceutical Company (JP), Bio Farma (ID) |
| Segments Covered | type, end users |
| Key Market Opportunities | Emerging technologies in vaccine delivery systems enhance accessibility in the Human Rotavirus Vaccine Market. |
| Key Market Dynamics | Rising demand for Human Rotavirus Vaccines driven by regulatory support and increasing awareness of pediatric health. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Human Rotavirus Vaccine Market?**
A: As of 2024, the market valuation stands at 11.3 USD Billion.

**Q: What is the projected market size for the Human Rotavirus Vaccine Market by 2035?**
A: The market is expected to reach a valuation of 24.15 USD Billion by 2035.

**Q: What is the expected CAGR for the Human Rotavirus Vaccine Market during the forecast period 2025 - 2035?**
A: The market is anticipated to grow at a CAGR of 7.15% from 2025 to 2035.

**Q: Which companies are the key players in the Human Rotavirus Vaccine Market?**
A: Key players include GlaxoSmithKline, Merck & Co., Sanofi Pasteur, Pfizer, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, and Bio Farma.

**Q: What are the revenue projections for the Rotarix vaccine from 2025 to 2035?**
A: Revenue for Rotarix is projected to grow from 3.5 USD Billion to 7.5 USD Billion during this period.

**Q: How does the revenue of RotaTeq compare to that of Rotarix in the forecast period?**
A: RotaTeq is expected to generate revenue between 3.0 USD Billion and 6.5 USD Billion, which is slightly lower than Rotarix.

**Q: What is the expected revenue range for hospitals and clinics in the Human Rotavirus Vaccine Market?**
A: Revenue from hospitals and clinics is projected to increase from 6.78 USD Billion to 14.25 USD Billion by 2035.

**Q: What segment shows the highest growth potential among end-users?**
A: Pediatricians are expected to see revenue growth from 4.5 USD Billion to 10.5 USD Billion, indicating strong demand.

**Q: What is the projected revenue for the rotavac vaccine from 2025 to 2035?**
A: The rotavac vaccine is anticipated to generate revenue between 2.0 USD Billion and 4.5 USD Billion during the forecast period.

**Q: How do academic and research centers contribute to the market's growth?**
A: Revenue from academic and research centers is expected to rise from 4.52 USD Billion to 9.9 USD Billion, reflecting their crucial role in vaccine development.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/human-rotavirus-vaccine-market-4171*